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           Till minnet av Seba 
  
”The course of nature” is a term easer for a doctor to say than a family member 
to understand! 
 
My mentor says it’s not fair….. it’s never fair! 
 
I had an aunt… she was very close friend… young and beautiful….. 
One day she was diagnosed for breast cancer. For more than ten years ago it 
was very much as consent to death. One operation and multiple chemotherapy 
and radiotherapy courses but six months later brain metastases appeared and a 
month later she fell for her long-last sleep.    
 
Seba was at the age of 32 when she died leaving a husband and a six years old 
daughter behind. “Time heals all wounds” I can’t agree. We have learned how 
to live without you but it’s always painful to think about you. You are there in 
our thoughts and you will always be there!    
 
I promised myself to do everything in my hands to help to improve cancer 
therapies and I’ll always do until the last day in my life.    
 
Dhifaf 
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ABSTRACT 
In the mid-70s, the term “natural” was used based on the functional properties of NK cells 
where they recognize and lyse certain tumor cells without requirement of prior 
immunization. Although NK cells are “natural” in their targeting of tumors, their 
responses in the tumor microenvironment have been very challenging to determine. The 
tumor microenvironment is known to consist of a heterogeneous population of cells and 
secreted factors. The failure in the immune surveillance may in part be due to sustained 
immunological selection pressure on tumor cells resulting in the development of tumor 
escape variants that are effectively invisible to the immune system. On the other hand it 
can be due to the complex network of immune suppressive compartments in the tumor 
microenvironment.   
We have studied NK cell activity in the tumor microenvironment. The study was divided 
into two parts; 1) how to augment NK cell activity against tumor cells, and 2) examine the 
suppression of NK cells in the tumor microenvironment. 
A novel proteasome inhibitor (b-AP15) was found to sensitize tumor cells of different 
origin to NK cell and T cell- TRAIL mediated killing. Combined therapy with b-AP15 
and infusion of NK cells and T cells in animals resulted in reduced tumor progression and 
prolonged survival. We also found that enhancement of TRAIL expression on NK cells 
could augment their cytotoxicity against tumors. Such action was possible when NK cells 
were interacting with monocytes that were manipulated with a bisphosphonate called 
Zoledronic Acid to produce IFN-γ. 
Studies on suppression of NK cells involved the outcome of interaction between NK cells 
and dendritic cells (DC) or myeloid-derived suppressor cells (MDSC), both in vitro and in 
cancer patients. We found that both DC and MDSCs suppress NK cell responses in 
patients with cancer. STAT-3 phosphorylation status in DC determined NK cell 
responses. Furthermore, the crosstalk between DC and NK cells was regulated through 
production of LTA, IL-12, and TGF-β. We found that prostaglandin E2 (PGE2) converts 
healthy monocytes to MDSC-like cells. Similar to patient-derived MDSCs, PGE2-treated 
monocytes showed increased phosphorylation of p38MAPK/ERK and suppressed NK 
cell responses by the production of TGF-β. 
In this thesis, new strategies to improve NK cell-based therapy have been suggested and 
new findings about the mechanisms of suppressing NK cells in the tumor 
microenvironment have been revealed. 
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1 INTRODUCTION 
 
The advantage of writing a thesis unlike writing a scientific paper is that for the first time 
as a scientist I can freely express myself without adhering to journal guidelines.  
 
In this thesis I will describe my research findings but first give an introduction to relevant 
areas in the field of immunology to help understanding my work. For detailed information 
about basic immunology, text books such as Cellular and molecular immunology (1), and 
Janeway’s Immunobiology (2), are recommended.   
The introduction is divided into two parts where the first part describes important aspects 
of the immune system and the second illustrate the advances in basic and applied tumor 
immunology with a particular focus on natural killer (NK) cells. Though my work has 
mainly focused on human immunobiology in healthy individuals as well as in cancer 
patients, I have also used animal models to test our hypotheses. 
 
With a new generation comes new ideas and what we know today is likely to be changed 
tomorrow. As a researcher in life sciences, I am blessed with the opportunity to be 
involved in such process. In this thesis, you will notice novel findings, which have added 
new considerations to the field of tumor immunology. 
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1.1 THE IMMUNE SYSTEM 
 
Billions of microorganisms that may cause different diseases surround human body; 
therefore, mechanisms of defense are needed. Immunity,  from Latin immunitas and 
means status of protection was first defined in the 1880s as a result of Jenner's, Pasteur's 
and Koch's work where they showed that entry of specific microorganisms may cause a 
certain disease and such illness can be prevented by vaccines that are extracted from the 
same pathogen (3). In 1890s, the natural and the artificial immunity were described as the 
following; Natural immunity is the resistance to pathogens from the first encounter, 
whereas the artificial immunity is to resist diseases caused by microorganisms that were 
hosted by the body in an earlier time point (4). Today we know that the immune system 
consists of cellular immunity and soluble factors. It is further classified conventionally 
into innate- and adaptive-immunity. According to immunology text books, the innate 
immunity, also called native or natural immunity, is the first line defense against 
microbes. Cells of the innate immune system include phagocytes (monocytes, 
macrophages, and dendritic cells) and natural killer cells. Additionally, soluble factors 
such as cytokines (small proteins that work as messenger, regulators, and sometimes as 
killers) do also belong to the innate immunity (5). In contrast, adaptive immunity 
responds slower to primary infections compared with the innate immune system.  
However, cells of the adaptive immune system (T cells and B cells) are specific and have 
a more powerful response when encountering pathogens for the second time (1, 5). 
Soluble factors of the adaptive immunity are antibodies that are produced by mature B 
cells (6). A very important distinction between innate from adaptive immunity is that the 
adaptive immunity can develop memory and can respond much faster upon rechallenge 
with the same pathogen (2).  
 
Among the innovative steps to immunize for different pathogens was taken in the 18
th
 and 
19
th
 century by the English physician Benjamin Jesty who started his work of cowpox 
vaccine that even resulted in immunization against smallpox, more than 20 years before 
Edward Jenner (7, 8). The idea of Jesty was to inoculate material from a sick cow in 
healthy individuals starting with his family (9). On the other hand, the credit was given to 
Jenner due to his exceptional work to development vaccines and eradication of smallpox 
(10). At that time, the dairymaids were generally known to be protected from the 
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smallpox. Jenner was inoculating an 8-years old boy with material from fresh cowpox 
lesions from a dairymaid. About a week later the boy developed a mild fever. Two 
months later Jenner was inoculating the same boy with a matter from fresh lesions from 
smallpox. The boy developed no disease and Jenner concluded that he was protected (11). 
This was the first footstep towards immunizing small children from common diseases. In 
the line with these discoveries, Louis Pasteur in the 19
th
 century, took the development of 
vaccines to an advanced level, where he immunized with killed pathogenic agents to 
prevent development of diseases (12). Later in the 19
th
 century Paul Ehrlich a German 
Jewish scientist laid the foundation for antibodies development describing, a specific 
antigen can (antigen from antibody generator: is a foreign or “self” element that provoke 
immune responses) generate an antibody response (13).   
 
The immune system is a complex network but very much regulated. The early discoveries 
led to today’s knowledge. Below, components of the immune system, relevant for this 
thesis are described.  
 
 
 Monocytes and Dendritic cells of the innate immunity 1.1.1
Monocytes are large leukocytes originate from the myeloid lineage. They have 
different functions and participate in many essential innate immunity responses 
including phagocytosis, and cytokines production (14, 15). Circulating monocytes 
differentiate to macrophages and dendritic cells when resident in the tissues (16). 
They are also divided to two subsets; the classical subset is expressing high CD14, 
the co-receptor for Toll-like receptor (TLR)-4 to recognize bacterial 
lipopolysaccharide (LPS). They display an antibody-dependent cell-mediated 
cytotoxicity (ADCC) (17). However, under certain conditions, they can also 
suppress activated lymphocytes (18, 19). The other subset of cells express low 
levels of CD14 and high level of HLA-DR, a good presenter of peptides derived 
from viruses and bacteria, and also produces high levels of interferon-alpha (20, 
21). The majority of monocytes do not express FcγIII receptor (CD16), however 
about 10% of the blood circulating do. Those monocytes expand by cytokine 
treatment including; GM-CSF, M-CSF, and IL-3 and also during inflammatory 
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conditions like, coronary artery disease and chronic kidney disease (22-26). 
Monocytes display plasticity and can function as pro-inflammatory and anti-
inflammatory when needed (27, 28). Pro-inflammatory monocytes can stimulate 
both memory T cells and NK cells in a cytokine-dependent manner during 
microbial invasion (29-31). In allergic reactions monocytes are recruited to the site 
of inflammation to dampen such reaction as an anti-inflammatory component (32).  
 
Dendritic cells (DC) originate from either myeloid or lymphoid progenitors (33-
35) (Figure 1).  
 
In mice, DC are divided into classical DC (cDC), plasmacytoid DC (pDC), and 
Langerhans cells (LC). Those subsets are divided further to unique groups of DC 
according to their surface antigen expression and location. The cDC are found in 
lymphoid tissues with either CD8
+
CD11C
+
CD11b
-
 or CD8
-
CD11C
+
CD11b
+ 
phenotype (36, 37). In non-lymphoid tissues, are they either CD103
+
CD11b
-
, 
CD103
-
CD11b
+
, or CD103
+
CD11b
+
 in intestine (38, 39). pDC are blood and 
spleen residents characterized by expressing low levels of major 
histocompatibility complex (MHC) class II and CD11c but produce high levels of 
type I IFN (40). LC populate the skin and express high level of langerin and are 
CD11b
+
F4/80
+ 
(41).    
 
In humans it is more complicated to distinguish DC subpopulations where many 
surface markers are shared with other hematopoietic cells such as monocytes and 
macrophages (42), DC are typically divided into conventional/classical DC (cDC), 
plasmacytoid DC (pDC), Langerhans cells, and monocyte-derived DC (mDC) (43, 
44). cDC are found in the blood circulation under both steady and inflammatory 
conditions and express high level of CD11c, CD1b/c and BDCA3. They are 
highly migratory and generally short-lived in the blood. (43, 45). In contrast, mDC 
were primarily included in the non-conventional DC since they do not 
differentiate in normal conditions but only during inflammatory conditions (46, 
47). Yet, recent studies have suggested that mDC exist in intestines, and muscles 
in a steady state (48, 49). pDC are long-lived cells usually found in the circulation 
or lymphoid tissues. They express low levels of MHC-II and CD11c with high 
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ability to produce IFN-α when stimulated. LC, sometimes referred to “skin DC”, 
mainly reside in the epidermis (50, 51). 
 
      
 
 
Figure 1: Hematopoietic tree for dendritic cell development. Hematopoietic stem cells (HSC) in 
the bone marrow give raise to multipotent progenitors (MPP). Further downstream, lineage 
differentiation splits to common myeloid progenitors (CMPs), or common lymphoid progenitors 
(CLPs). CMPs then further differentiate into granulocyte/macrophage progenitors (GMPs). 
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Macrophage-DC progenitors (MDPs) give rise to monocytes and conventional DCs (cDCs), and 
plasmacytoid DCs (pDCs). MDPs-derived monocytes can further differentiate into inflammatory 
DCs and Langerhans cells. CLPs can give rise to both common DC progenitor (CDP) and pDC.  
 
 
DC are typically referred to as professional antigen-presenting cells. To activate 
naïve T cells, DC deliver three typical activation signals, stimulatory signal 1 
presenting of antigens to T cell receptor (TCR), co-stimulatory signal 2 when 
binding to CD28 co-stimulatory receptor, and polarization signal 3 which is 
mediated by cytokine or membrane-bound stimulation like IL-12 or CCL2 (52).      
 
 
 Cytokines 1.1.2
Cytokines are small proteins involved in diverse biological responses including; 
proliferation, cell growth, cell differentiation, inflammation, defense against 
microbes, etc. (1, 53-56). Cytokines are produced by many different cell types like 
leukocytes and some epithelial and endothelial cells. They act by binding to their 
receptors which are expressed selectively on specific subsets of cells. Failure to 
produce cytokines or dysregulation of their function can lead to different diseases 
including autoimmune diseases and cancer (57-59). There are different cytokine 
families including the interleukins (IL), the tumor necrosis factors (TNF), and the 
interferons. Among the first described ILs is IL-2, which is essential for 
proliferation, survival and enhancement of killing of T- and NK-cells (60-62). 
Together with other cytokines IL-2, IL-15, IL-12, IL-6, TNF-α, lymphotoxin-
alpha (LTA), and IFN-γ belong to a group called proinflammatory cytokines due 
to their ability to induce inflammation (63, 64). In contrast, cytokines like IL-10 
and TGF-β are anti-inflammatory cytokines due to their involvement of 
suppressing immune responses (65-67).            
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 T cells of the adaptive immunity 1.1.3
Optimal defense against different microorganisms needs the action of the adaptive 
immunity. Such action can be derived by thymus-derived (T) cells, using antigen-
specific receptors to mediate effector responses in two steps. First, when T cells 
are primed by antigen-presenting cells (monocytes, macrophages, DC, and B 
cells) in the secondary lymph node, they become activated, differentiate to 
different subsets depending on the received signal and proliferate. Primed T cells 
then migrate to the site of infection in response to chemokines usually produced 
by innate immune cells that are already presented at the site. T cells of the 
adaptive immunity are typically classified as CD4 Th1 inflammatory cells that 
activate macrophages, CD4 Th 2 help to generate antibody responses, regulatory T 
cells negatively regulate effector cells,  and importantly CD8 cytotoxic cells that 
are able to mediate direct killing of the target (1, 6) (Figure 2).    
 
   
 
 
Figure 2: Differentiation of T cells into different subtypes. 
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 Antigen processing and presention 1.1.4
The classical way to present antigens is on the molecular complex of the MHC 
class I or II. MHC molecules present either endogenous (intracellular) or 
exogenous (extracellular) proteins (68). The process of antigen presenting begins 
with proteolytic degradation of the aimed protein. The process of degrading 
proteins is a very important biological act in the cell to dispose of accumulated 
and destroyed proteins (69, 70). The proteasome system is utilized for such 
purpose. The proteasome is a multi-subunit complex consist of 20S core unit and 
different regulatory subunits that bind to the 20S, like the 26S and 19S to modify 
and select degradation (71). All proteasomes have similar structure consisting of 
three subunits yet the immunoproteasome containing the 20S core unit and one 
regulatory unit such as 19S or 11S (72) (Figure 3). The immunoproteasome is 
used in the MHC class I restricted antigen presenting (73, 74).  
 
 
 
 
 
 
 
Figure 3: Proteasome and immunoproteasome multi-subunit structure consisting of core subunit 
and regulatory subunits.   
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 Endogenous antigen presenting- MHC I 1.1.4.1
Cytotoxic T cells (CD8
+
) are activated by MHC class I molecule. Such molecule 
is expressed on all nucleated cells this means all cells can present antigens to 
CD8
+ 
T cells. The MHC I molecule is presenting cytosolic antigens that can be 
products of viruses, other intracellular microbes, or tumor cells. Other source of 
antigens is phagosomes (vesicles) that carry microbes or products of pathogens 
which internalize to the cell cytosol and be processed as the other cytosolic 
antigens. Following processing, antigens are transported to the endoplasmic 
reticulum (ER) by transporter associated with antigen processing (TAP), packed 
on an MHC I molecule and via the Golgi transported with exocytic vesicles to the 
cell surface (1) (Figure 4). 
 
 
 Exogenous antigen presenting- MHC II 1.1.4.2
MHC class II molecules are expressed on few cell types, as such antigen 
presenting cells. On MHC II molecules are the exogenous antigens presented to 
the CD4
+
 T cells. On the other hand a process called cross-presentation enable 
exogenous antigens to be presented on the MHC I. Unlike the endogenous 
presenting, the loading of MHC II is occurring outside the ER where only MHC II 
is processed following a loading step inside the fused endocytic and exocytic 
vesicles in the cytosol and finally presented on the cell surface (1) (Figure 4).  
 
  
 
  17 
 
 
 
 
Figure 4: Classical antigen presentation. Antigens are either presented by MHC class I or II 
molecules that requires different processing and loading of the antigens. 
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 NK cells 1.1.5
 
 NK cell identification 1.1.5.1
In the mid-70s, the term “natural” was used based on the functional properties of 
NK cells where they recognize and lyse certain tumor cells without requirement of 
prior immunization (75, 76).  
 
NK cells consist of 5-15% of the blood circulating lymphocytes and described as  
large granular lymphocytes of the innate system due to their inability to rearrange 
their receptors from their germline configuration (77, 78). They are identified by 
the expression of CD56 and lack of CD3. CD56 (NCAM) is found on human NK 
cells but not on those of murine origin (79). However, studies have suggested that 
a natural cytotoxic receptor NKp46 can be used as an identification marker of NK 
cells across different species (80, 81). In conflict, a subset of human NK cells lack 
or express very low NKp46 which results in difficulty to identify NK cells 
therefore, they have to be determined by the lack of other lineage markers (82).        
        
 
 NK cell development 1.1.5.2
The localization where NK cell development occurs in humans has been argued. 
Though they originate from bone marrow CD34
+
 hematopoietic progenitor cells, 
their differentiation into mature cells are not thought to take place in the bone 
marrow (83). Instead, NK cells are believed to mature in the lymphoid tissues due 
to the lack of immature and intermediate matured NK cells in the bone marrow. 
On the other hand, in vitro studies have shown that CD34
+
  cells are differentiated 
to NK cells by cytokines which are normally produced by immune cells located in 
the bone marrow  (82, 84, 85).  
 
 
Human NK cells are divided into to two subtypes based on their expression level 
of surface CD56. CD56
bright
 (high level of CD56) are marked as 
immunoregulatory cells with remarkable cytokine production capacity and 
resident of the lymphoid tissues, while CD56
dim
 (low expression of CD56) 
constitute 90% of NK cell population are circulating in the blood. Unlike 
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CD56
bright
, CD56
dim
 express high levels of CD16 and have potent cytotoxic 
functions (Figure 5) (86, 87). Cells expressing CD16 are able to kill target cells 
via antibody-dependent cell-mediated cytotoxicity (ADCC) (88).     
 
 
 
 
 
 
Figure 5: Different NK cell subsets classified depending on their expression levels of CD56 and 
CD16 expression. CD56
dim
 is the cytotoxic NK cell and CD56
bright
 is the immunoregulatory NK 
cell. 
 
 
 
 
 
  Inhibitory receptors 1.1.5.3
NK-cell function is regulated through a balance of inhibitory and activating 
receptors. The final response is predicted by the strength of binding or lack of 
binding of the inhibitory receptors. The largest group of inhibitory receptors are 
the killer immunoglobulin-like receptors (KIRs) that bind to the MHC class I 
complex (89). In the beginning of the 80s, Kärre and co-workers observed that the 
murine tumor cell line YAC-1, expressed low levels of MHC class I molecules, 
were sensitive to killing by NK cells (90). These observations later led to the 
formulation of the “missing-self” hypothesis (Figure 6) (91). 
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Figure 6: The “missing self” model. NK cell inhibition mediated by KIR ligation of MHC I 
molecule in normal cells. When cells are transformed and lose their MHC I expression the 
inhibition of NK cells has disappeared and they are able to kill their target.  
 
 
 
In the 1992 in the laboratory of Yokoyama, the first inhibitory receptor Ly49 
expressed on murine NK cells was identified (92). Later, in the beginning of the 
90s, Moretta and colleagues were first to discover the human KIRs of the NK cells 
(93-95). Another inhibitory receptor expressed by NK cells is the CD94/NKG2- 
inhibitory receptor (96). 
 
 
 
 Activating receptors 1.1.5.4
In addition to inhibitory receptors, NK cells also express activation receptors. One 
of the most studied receptor is FCRγIII (CD16), which is expressed on the 
majority of the NK cells and binds the constant region (Fc) of IgG (86, 97). CD16 
is the only receptor that activates NK cells by itself (98, 99). Among other 
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important activation receptors are, NKG2D which ligate the stress induced 
molecules MICA/B or ULBP-proteins, and natural cytotoxic receptors (NCRs, 
NKp30, NKp46, and NKp44) (100-105). The ligands to the NCRs are not very 
well studied. What is known today, the two described NKp30 ligands BAT3 and 
B7-H6 and hemagglutinin (HA) a viral protein that ligate NKp44 and NKp46 
(106-110). Add to the list, the activation co-receptors that are involved in the 
regulation of NK cell reactions to the target including; DNAM-1 and NKp80 
(Figure 7) (111, 112). These activating receptors play an important role in 
stimulating NK cells in different pathogenic and in cell transformation conditions.  
 
 
 
 
 
 
Figure 7: NK cell receptors. NK cells interact with their target by integrating inhibitory and 
activation receptors. 
 
 
As such action, ADCC has been widely recognized as a process to target virus-
infected cells as well as tumor cells (113, 114). The expression of different 
activation or inhibitory isoforms of NKp30 in gastrointestinal sarcoma patients 
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predicts the clinical outcomes (115). In the line of the diversity of NK cell 
responses is the ligation of NKG2D by MICA/B or ULBP proteins has been 
shown to induce cytotoxic activity against hepatoma cells (116). The co-receptors 
of the NK cells have been revealed to be important for fighting cytomegalovirus-
infected cells and might play a role in the tumors where NK cells display an 
altered phenotype (117, 118).  
 
Importantly, the above mentioned receptors except CD16, need to cooperate with 
each other to stimulate NK cell action (119). For instance, activating NKp46 alone 
is not sufficient to activate NK cell degranulation; however co-activating DNAM-
1, NKG2D, or 2B4 was required for NK cells to degranulate (99).         
 
 
 
 
 Regulation of NK cell receptors 1.1.5.5
During the development of NK cells, receptor expression is highly regulated to 
avoid autoimmunity or hypoactivation. Intensive investigations of how the KIR 
family expression is regulated have shown that NK cells normally in healthy 
individuals express at least one KIR. However, there are a heterogenic repertoire 
expressed among the cells (120). There are few ideas of how the expression of NK 
cell receptors is regulated. One of those is NK cell education or licensing, such 
idea mimics the theory behind TCR repertoire except that NK cell receptors are 
not rearrangeable. NK cells undergo an educational process by binding diverse 
MHC I molecules to their KIRs. Studies in mouse-models have shown that NK 
cell licensing is associated with a correlation of self-MHC class I expression and 
expression of an inhibitory receptor for a self-MHC class I on NK cells (121). 
Such interaction is needed for a fully responsive NK cells and for self-tolerance 
(122). 
 
In the line of regulating receptors, a very strong regulator of the activation 
receptors is the receiving of proinflammatory respectively anti-inflammatory 
cytokines including; IL-12, IL-15, TGF-β, and IL-10 (123-126). Although, there 
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are accumulating studies examining the regulation of NK cell receptor expression 
in different human disorders, we still lack the complete understanding of such 
processes especially in cancer patients.  
 
 
 
 NK cell cytotoxic action 1.1.5.6
Following activation or lack of inhibition, NK cells produce pro-inflammatory 
cytokines like IFN-γ and TNF-α (127-130). In response to target cells, NK cells 
integrate by their adherent molecules like LFA-1 resulting in Ca
+
 release which 
further polarize cells, and degranulate the perforin containing lytic granules (131, 
132). Other direct killing mechanism involves ligation of death receptors. Death 
ligands expressed on the surface of NK cells, including TNF-related apoptosis-
inducing ligand (TRAIL) and Fas-ligand (FasL) bind to their cognate receptors 
expressed on target cells. While the FasL binds to its only receptor Fas, TRAIL is 
binding to four known membrane-bound receptors and one soluble receptor 
(Figure 8). TRAIL-receptors DR4 and DR5 acting in two steps initiated by 
binding their extracellular domain to TRAIL which results in transforming the 
signal to the intracellular domain, such signal recruit and activate the caspase in 
turn initiate the apoptotic signal-transduction pathway (133). Normal cells usually 
are discriminated from transformed cells by expressing the other two membrane-
bound TRAIL-receptors called decoy receptors DcR1 and DcR2 which either lack 
or have no functional intracellular death-domain (134-137).  
 
 
 
 
 
  
 
24 
 
 
 
 
Figure 8: Human TRAIL-R expression. Different TRAIL-R extracellular and intracellular 
domain expression in human normal cells. The figure is modified form Front Biosci. 2007 May 
1;12:2912-21. 
 
 
 
 Memory NK cells 1.1.5.7
NK cells are traditionally described as short-lived innate lymphocytes with a 
limited proliferative capacity and the lack of antigen specificity. However, recent 
studies have challenged this dogma by demonstrating unexpected observations 
that NK cells display adaptive immune characters. O'Leary et al. demonstrated 
that a subpopulation of liver-resident NK cells is capable of mediating specific 
hapten-induced responses in mice lacking T and B cells in terms of a second 
challenge (138). CMV infection may result in the generation of memory NK cells 
in mouse models (139). The NK cell memory is still a new concept that has been 
evaluated mostly in virus-infection models (140). Further investigations in other 
diseases models are required. 
  
Apoptosis 
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NK cell respond differently in healthy and in disease conditions. In the next 
session the NK cell responses in the tumor microenvironment are discussed. 
 
 
   
 
1.2 TUMOR IMMUNOLOGY 
 
The hallmarks of cancer comprise six biological capabilities acquired during the 
multistep development of human tumors. These include; sustaining proliferative 
signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis (141). 
Progress in tumor biology research has added two new hallmarks; reprogramming of 
energy metabolism and evading immune destruction (142).  
 
 Immune surveillance 1.2.1
The role of the immune system in controlling transformation cells was very 
controversial in the 1909 when Ehrlich first suggested the idea (143). Later during 
1950s Burnet revised the topic “natural” protection against tumors. Burnet 
believed that tumor cell-specific antigens could break the immune tolerance and 
provoke an effective immunologic response that results in eliminating 
carcinogenesis (144, 145). Eventually, the idea was accepted in the 1990s when 
the approach of transgenic mouse-models led to the validation of tumor immune 
surveillance both in chemical induced as well as spontaneous tumors. At that time 
the role of effector cells as T-, B-, and NK-cells, and interferons was confirmed to 
be critical (146-148).  
 
Another evidence for immune surveillance was emerged in transgenic mice 
lacking the gene RAG that is essential for rearrangement of immunoglobulin and 
T cell receptors were subcutaneously injected with the chemical carcinogen 3′-
methylcholanthrene (MCA). 60% of the mice developed sarcomas compared with 
19% of the WT mice (148). Additional evidence support the immune surveillance 
is, immunosuppressed transplant recipients that have an increased risk of 
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developing cancers (149, 150). Finally, in the last decade several studies from 
cancer patients have shown that high numbers of infiltrated lymphocytes, 
especially T cells correlate with good prognosis (151-154).    
 
 
 Immune escape 1.2.2
There are several factors that inhibit or generate the development of cancer. Such 
factors can be mediated by the transformed cells (tumor-cell-intrinsic) or by the 
surrounding (tumor-cell-extrinsic). The development of cancer involving three 
important steps of the cancer immunoediting namely, the “3 Es” model; 
elimination, equilibrium, and escape (Figure 9).  
 
 
 
 
 
Figure 9: Tumor immunoediting. The balance of tumor immunosuppression and immune cell 
action. 
 
 
 
The elimination is a process of protection from uncontrolled growth that results in 
eradicating the damaged cells by the immune system i.e. immune surveillance 
(155-157). Proceeding to the next step “equilibrium”, when tumor cells resist the 
immune effector cells under long time, consequently they become less 
immunogenic, emerging immune selection of tumor cells where more resistant 
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cells survive (158). The final step is when the immune system has no or very 
limited control on the tumor mass, here the tumor immune “escape” has been 
reached (159).  
 
The immune escape by tumors is recognized and can be divided into three 
categories; loss of recognition, absence of susceptibility, and induction of immune 
suppression (160). One of the most known examples of loss of recognitions is the 
failure to present tumor specific antigens where T cells are no longer able to 
recognize those (161). Furthermore, tumor cells usually, turn off signals, down-
regulate, or shed receptors or ligands that are necessary to induce killing by 
effector cells which results in tumor lack of susceptibility (162-164).       
    
 
 Tumor microenvironment 1.2.3
The tumor microenvironment is known to consist of a heterogeneous population 
of cells and secreted factors including; not only the tumor cells, but the immune 
cells and cytokines. In this session, selected cell populations and factors involved 
in the tumor microenvironment are described.  
 
 
  Intrinsic factors: Membrane bound proteins  1.2.3.1
During immune editing, tumor cells lose or over-express different proteins that 
might be very important for immune recognition or suppression. HLA-molecules 
are of fundamental importance for T cell priming and activation. Failure to present 
antigen has been observed both in murine tumor models and in cancer patients. 
Such deletion of antigens is mediated by mutations in the antigen-presenting 
machinery or due to HLA complete loss, or even loss of the antigen expression 
(161, 165, 166). Tumor cells that have lost the expression of MHC class I are 
insensitive to killing by T cells. Instead, such tumor cells are sensitive to killing by 
NK cells. However, tumor cells can resist NK cell killing via down-regulation or 
shedding of death receptor Fas, and stress ligands for NKG2D, or down-
modulating TRAIL-receptor-mediated apoptosis by upregulating cFLIP (167-
169).   
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Recently, much attention has been paid to the programmed death ligands 1 and 2 
(PD-L1/PD-L2) that are expressed on wide range of tumors. They interact with the 
receptor PD-1 that is found on activated immune cells to prevent hyperactivity 
(170-174). Upon interaction with tumor cells both NK cell and T cell antitumor 
activity is impaired and clinically correlated with poor prognosis (175-177). Other 
similar molecules that are overexpressed and inhibit T cell and NK cell functions 
by integrating with tumors are CTLA-4, HLA-G, and HLA-E. Note that these 
molecules act early to mediate immune-suppression (178-181).  
 
 
 Intrinsic factors: tumor-induced transcriptions factors 1.2.3.2
Another type of immune-suppression mediated by tumor cells is the high activity 
of certain transcriptional factors namely, signal transducer and activator of 
transcription (STAT)3 that is constitutively phosphorylated in many tumors (182, 
183). STAT3 activity in tumors has been associated with inhibited immune 
surveillance by CD8
+
 T cells and Th1 cells (184, 185). The STAT3 activity of 
tumors induces production of suppressive cytokines as IL-10 and TGF-β (186, 
187).        
 
 
 Secreted factors in the tumor microenvironment 1.2.3.3
The factors secreted in different cancers might by different in the type and the 
amount, however “master” regulators seems to be commonly produced. Among 
these suppressive factors are TGF-β (188), IL-10 (189), IL-6 (190), GM-CSF 
(191) and inflammatory mediators like Cyclooxygenase (COX-2) and 
prostaglandin E2 (PGE2) (192). The suppressive cytokines as TGF-β within the 
microenvironment block for instance the differentiation and maturation of 
dendritic cells which results in inhibited cross-presentation of tumor-antigens to 
the T cells (193). Another potent inhibitor is IL-10 where it has a direct effect on 
the production of TNF-α and IFN-γ by NK cells and T cells. It also inhibits the 
cytotoxic effect of macrophages and their ability to produce IL-12 (194, 195). The 
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immune-modulators mentioned above contribute to a cascade of inflammatory 
responses that promote cancer progression by inhibiting DC, skewing cytokine 
production, enhancing angiogenesis, and inhibiting apoptosis (196-199). 
Collectively, tumor progression is frequently associated with severe impaired host 
innate and adaptive immune responses. 
 
The immune-suppressive environment of tumors includes complicated 
mechanisms and involvement of many immune cells and factors. Therefore it is 
impossible to include all of them in this thesis. In the next session the role of NK 
cells and their interaction with tumor cells and selective immune-suppressive cells 
is highlighted.    
 
    
 Immune suppression of NK cells 1.2.4
In order to understand NK cell responses against cancer we need to know more 
about how NK cell interact with not only tumor cells, but how they perform in the 
tumor microenvironment.   
 
 
 Immune-suppressive compartements: Regulatory T cells 1.2.4.1
One of the most studied immune-suppressive cell type associated with tumor 
progression is regulatory T cells (Treg). They are characterized by their expression 
of CD4, CD25, CD127 (CD4
+
CD25
+
CD127
low/neg
) as well as the transcription 
factor forkhead box P3 (FoxP3) (200). The expansion of Treg is promoted in 
different cancers and their accumulation correlates with impaired immune cell-
function and poor prognosis (201-206). NK cells are suppressed by Treg in a cell-
contact dependent manner where membrane-bound TGF-β is utilized to attenuate 
their cytotoxicity (207). Importantly, Treg express the high affinity IL-2 receptor-
alpha (IL-2Rα) and need IL-2 for their full-function. They consume IL-2 that is 
produced by other cells suggesting the idea of IL-2 deprivation as a mechanism of 
suppression of T cells and NK cells (208, 209).                
 
 
  
 
30 
 
 
 Immune-suppressive compartements: Myeloid-derived suppresor cells 1.2.4.2
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of 
precursors of granulocytes, macrophages, and immature DC with suppressive 
activity (210). Recently, myeloid-derived suppressor cells (MDSCs) have been 
proposed as key immuneregulators in various solid and hematologic malignancies 
(211, 212). MDSC are divided into two groups the granulocytic (grMDSCs) and 
the monocytic MDSCs (moMDSCs) (213). In mice grMDSCs are characterized 
by expressing CD11b, Gr-1, Ly6G, and low Ly6C and moMDSC by CD11b, Gr-1, 
high Ly6C, and lack of Ly6C (213). In humans, distinct phenotypes of MDSCs are 
associated with different types of cancers (214-218). Their suppressive function is 
mediated by different mechanisms however mostly through suppressive cytokines 
including IL-10 and TGF-β or by depleting their surrounding by arginine or by 
production of reactive oxygen species (ROS) (Figure 10) (215, 219-222). Recent 
studies have aimed to investigate the induction mechanism of MDSCs and how 
they suppress T cells in vitro (223-225). Despite what is identified about the 
interaction between T cells and MDSCs, much less is known about how NK cell 
responses are influenced by these cells. 
 
 
Figure 10: MDSC suppression. MDSCs apply different suppression mechanism on effector cells 
like NK cells, CD4 and CD8 T cells and also induce differentiation of other suppressive cells like 
Treg and TAM. The figure is a modification from J Immunol. 2009 Apr 15;182(8):4499-506.   
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 Immune-suppressive compartements: Tumor-associated macrophages 1.2.4.3
Macrophages are the dominant myeloid-derived population that is found in the 
tumor microenvironment. Tumor-associated macrophages (TAMs) are suggested 
to actively promote tumor growth and metastasis (226, 227). TAMs are 
characterized as a population of multiple distinct pro (M2)- and anti (M1)-tumoral 
subpopulations. The immune suppressive mechanisms applied by TAMs in the 
tumor microenvironment can be recruitment of Treg, direct and indirect inhibition 
of T cells, and production of IL-10 (228-230). 
 
 
 Immune-suppressive compartements: Immune-regulatory Dendritic cells 1.2.4.4
Recent studies of less understood cell population, suggest pro-tumorigenic 
myeloid-derived immune regulatory cells namely, immune-regulatory Dendritic 
cells (regDC). They are derived from cDC and their infiltration in the tumors 
correlates with poor clinical outcome (231, 232). In a pre-clinical study of lung 
cancer, shows accumolation of regDC support tumor growth and suppress anti-
tumor activity (233).       
 
 
 
 Immunotherapy 1.2.5
Immunotherapy aims to strengthen the immune system to eliminate cancer. 
Immunotherapy can be divided into passive where anti-tumor effectors are 
provided (antibody therapy, cell therapy) and active specific (vaccines) or active 
non-specific therapy (cytokines) where patients own immune system is stimulated 
(listed below).  
 
Active immunotherapy 
1. The aim of tumor vaccines is to induce immune recognition of the tumor cells 
or to boost the already existing anti-tumor immune response. However, an 
important concern in such type of therapy is the low immunogenicity of 
tumors and already reduction of effective immune compartments. Such 
vaccines includes; Cell based (whole-tumor cell vaccine, DC-vaccine), or 
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tumor component based (DNA vaccine, antigen peptide vaccine, and 
exosome-based vaccine) (234-237).  
 
2. Cytokines are commonly used in immunotherapy for the purpose of 
stimulating the immune responses like differentiating, proliferating and 
activation of effector cells, and recruitment of APC. Such cytokines are IL-2, 
IFN-α, and GM-CSF, however these therapies have high toxicity rates due to 
their systematic administration (238). 
 
Passive immunotherapy 
1. Antibody-based therapy is one of the earliest strategies for cancer 
immunotherapy. Monoclonal antibodies (mAB) can direct kill the targeted 
tumor cells, stimulate component of the immune system (ADCC), or interfere 
with the inhibitory signaling pathways applied by the tumor cells. Theses 
mAB including; anti-CD20 (Rituximab), anti-HER2 (Trastuzumab), anti-
VEGF (Bevacizumab), anti-EGFR (Cetuximab), anti-CTLA-4 (Ipilimumab) 
(239). One major concern with long-term antibody-based therapy is 
development of resistance (240). 
 
2. Immune hyporesponsiveness is a major fact in the tumor microenvironment 
which initiated the idea about adoptive cell therapies with ex-vivo activated 
immune cells. Tumor infiltrating lymphocytes (TILs) have been shown to be 
reactive to host tumor-specific antigens, however inhibited in the tumor mass. 
Numerous studies have investigated the ability of expanding such cells ex-
vivo and transfer them back to the patients. Such treatment has shown 
remarkable success in melanoma patients (241).  Other T cell therapies include 
genetic modifications, specific-TCR transduced T cells and chimeric antigen 
receptor (CAR)-expressing T cells (242, 243). 
 
 
As mentioned above, the tumor microenvironment plays a significant role in 
suppressing the immune response against cancer. Therefore, therapies aimed at 
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targeting immunosuppressive cell populations are emerging. Below additional 
immunotherapy targets are described. 
 
 
 Targeting Treg 1.2.5.1
The therapeutic targeting of Treg has achieved progress with limited success. 
Several therapeutic agents have been suggested to reduce Treg numbers; however 
those agents do not target Treg specifically but also target effector cell function. 
Such therapies target Treg proliferation (244, 245), impair their function by the 
TLR-agonists (246). Recently, the use of mAB CTLA-4 suggested as a target for 
regulating Treg in cancer patients. However, pre-clinical and clinical studies show 
an accumulation Treg though an increased anti-tumor activity by effector T cells, 
suggesting the indirect effect of CTLA-4 treatment (247, 248).   
 
 
 Targeting MDSC 1.2.5.2
MDSCs do not express specific identification markers which make them difficult 
to selectively deplete. Instead, investigators have explored to deplete 
immunosuppressive factors produced by MDSCs. Therapeutic preclinical 
examinations of different strategies are suggested including blocking of MDSC 
differentiation, expansion, and their suppressive function (249). Amiloride is used 
in patients with hypertension though treating tumor-bearing mice with amiloride 
decreased the STAT3-dependent MDSC suppressive activity by inhibiting tumor 
exosome formation (250). Sunitinib, a tyrosine kinase inhibitor and target many 
growth factors like M-CSF and VGEF-receptors. Administration of Sunitinib in 
tumor-bearing animals targeted the expansion of MDSC and enhanced Th1 IFN-γ 
expression (251). PGE2 block the differentiation of APC from the bone marrow 
and induce MDSCs (252). COX-2 inhibitors like celecoxib and Acetylsalicylic 
acid (Aspirin) reduce the systematic level of PGE2 consequently, reduced the 
MDSC production of ROS and arginase as well as the chemoattractant of MDSCs 
CCL2 (253-255).      
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 Blocking immunological checkpoints 1.2.5.3
The aim of targeting immunological checkpoints is to accumulate the positive 
effect of the effector cells and eliminate the suppression effect of the suppressor 
cells like Treg and MDSCs in the tumors. Immunotherapeutic strategies were 
directed primarily on enhancing immune effector functions, as such CTLA-4 
blockade by mAB (Ipilimumab). Ipilimumab has been now used in several clinical 
studies in cancer patients with good objective responses and stable disease (256-
259). Another inhibitory member of the checkpoint proteins is the PD-1:PD-L1 
axis considering promise ability in rescue exhausted CD8+ T cells in murine 
models (259, 260) and prolonged survival in cancer patients (259). Interestingly, 
blockade of PD-1 decrease the suppressive effect of Treg and enhanced the 
cytotoxic function of effector cells (261).     
 
 
 DC vaccines 1.2.5.4
Given that DC are the most efficient APC, preclinical studies have been stressed 
to generate DC-vaccines in vitro. Monocyte-derived dendritic cells (mDC) 
generated in vitro, have been a great tool for generating DC-vaccines. 
Observations from independent studies, clarify that naturally occurring human 
mDC require IL-4 or GM-CSF to differentiate to mDC in vivo (262-264). 
Therefore such cytokines has been used in vitro to differentiate blood monocytes 
(265).  
 
In the last two decades maturation of blood monocytes to fully matured mDC in 
vitro has been driven for production of therapeutic vaccines for the benefit of 
cancer patients (266-270). Briefly, blood monocytes are differentiated to immature 
DC by IL-4 and GM-CSF following a maturation stage where different cytokines 
or TLR-agonists are utilized and loaded with tumor-specific antigens (271, 272). 
Production of therapeutic DC vaccines has been focusing on inducing effective 
anti-tumor immune responses in T cells. Although DC can elicit anti-tumor T cell 
responses (270, 273-275), the clinical benefit for patients with cancer has been 
marginal (276, 277). 
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1.3 NK CELLS IN THE CLINIC 
 
 Targeting KIR 1.3.1
There are numerous of studies to enhance NK cell anti-tumor activity against 
cancer. Initial efforts in the 1980s were done to infuse LAK (lymphokine activated 
killer cells)/NK cells in cancer patients with or without IL-2 administration, where 
few clinical responses were seen in these patients, thought to be paralyzed by the 
tumor immune-suppression (278-280). Today no complete tumor rejection has 
been shown following NK cell infusion in patients with solid tumors (281-283).  
However, more successful adoptive immunotherapy with NK cells has been 
presented in patients with hematological malignancies (284, 285). One of the 
central mechanisms that have been used in these successful therapies is avoiding 
the interaction of inhibitory receptors KIRs with cognate HLA and therefore 
selecting “mismatched” clones for adoptive transfer of NK cells (285-288). 
Therefore it is of high importance to assess the tumor phenotype if possible before 
NK cell infusion, to predict the susceptibility of tumors to NK cell lysing to select 
more beneficial NK cell clones or to select suitable patients for specific therapy.   
 
Such studies showing the clinical benefit of using mismatched NK cell clones 
emerged the idea of developing monoclonal antibodies to block KIRs. Completed 
phase I studies of anti-inhibitory KIR mAb IPH2101 in acute myeloid leukemia 
and in multiple myeloma, indicates a safe profile in the patients and can block 
KIR for prolonged periods of time with limited side-effects (289, 290). Evaluating 
NK cell activity in these patients identified roughly response parameters such as 
increased expression levels of CD69 and partially CD25 and elevated serum levels 
of TNF-α and the NK cell and monocyte chemoattractant MIP-1β (Figure 11). 
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Figure 11: Clinical trial with anti-KIR. NK cell expression levels of CD69 and CD25 were 
analyzed by flow cytometry and serum levels of TNF-α and MIP-1β were measured by ELISA. 
The figures are modified from original figures in Blood 2012;120:4324-4333 and Blood. 2012 Nov 
22;120(22):4317-23.    
 
 
 
 Sensitizing tumor cells to NK cell-mediated killing  1.3.2
Other therapies to render tumor cells susceptible to NK cells targeting have been 
suggested. Rituximab or Mabthera are specific chimeric antibody for CD20 have 
been developed to target B-cell lymphomas (291). Combinatorial studies with 
mAB and IL-2 showed that such treatment can mediate NK cell ADCC targeting 
of the tumor cells (292, 293). Therapies on augmenting death receptor-mediated 
killing of tumor cells by NK cells have recently been performed. Several in vitro 
and in vivo studies have shown that tumor cell killing is mediated by NK- or T- 
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cell TRAIL interaction. Pharmaceutical manipulations like proteasome inhibitors, 
anthracycline antibiotics, and histone deacetylase inhibitors, increase tumor 
susceptibility to NK cells by through enhanced TRAIL-R expression (294-298).  
 
 
 
 Improve NK cell anti-tumor activity   1.3.3
Resting NK cells have no or very low expression of death ligands (TRAIL and 
FasL). Therefore, efforts to up-regulate expression of death ligands on NK cells in 
order to augment the cytotoxic function of NK cells should be considered. 
Administration of cytokines , like IL-2, not only results in increased expression of 
death ligands on NK cells, but also support NK cell proliferation and cytotoxicity 
in vivo such as IL-2 (299-301). Substances such as Zoledronic acid and 
Lenalidomide have been shown in vitro to increase TRAIL expression on NK 
cells and that correlate with increased cytotoxicity (302, 303).  
 
Pre-conditioning has been shown to improve NK cell activity both in mouse-
models and in patients. Such treatment can be radiation therapy and/or 
chemotherapy. Such treatment increases NK cell recognition of the tumor cells by 
upregulating for instance stress ligands, make space for NK cells to proliferate and 
induce NK cell responses to the standard treatment (304, 305).  
 
Combining several strategies to enhance the activity and reduce the suppression in 
the tumor microenvironment is essential for efficient NK cell-based 
immunotherapy.   
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2 AIM OF THE THESIS 
The general aim of my thesis is to study NK cell activity in the tumor microenvironment. 
The study is divided into two parts; 1) how to augment NK cell activity against tumor 
cells, and 2) examine the suppression of NK cells in the tumor microenvironment.        
 
 
Part 1 
I. Pharmaceutical manipulations of established tumor cell lines to increase their 
susceptibility to NK- and T cell-mediated killing in vitro and in vivo.  
Enforcement of TRAIL-receptor expression on tumor cells 
 
II. Uncover novel strategies to increase TRAIL expression on NK cells to 
improve NK cell cytotoxicity against tumors 
 
 
 
Part 2 
III. Examine the interaction between NK cells and dendritic cells. Investigate the 
inhibitory effects of DC on NK cells. Develop new DC-vaccines to activate NK 
cells  
 
IV. Study the NK cell interaction with myeloid-derived suppressor cells. Examine 
mechanisms by which MDSCs inhibit NK cell anti-tumor activity   
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3 RESULTS AND DISCUSSION 
 
Immunotherapy against cancer has in the last 20 years become a field of great interest. 
Increased understanding of how NK cells recognize and kills malignant cells has sparked 
investigators to explore the therapeutical role of NK cells in patients with cancer. 
Nonetheless, tumor cells can escape innate and adaptive immunity and thereby limit the 
outcome of NK cell-based therapies. Aiming to increase the insights into the mechanisms 
applied by tumors to avoid immune responses has provided a good understanding of the 
complex system of the tumor microenvironment. Below is a description of four individual 
papers included in this thesis and discussion of the findings.  
 
 
 
Paper I: A novel inhibitor of proteasome deubiquitinating activity renders tumor 
cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells 
 
Tumor cells with a low or absent expression of MHC class I can be targeted by NK cells 
while tumor cells with a high expression of MHC class I can be targeted by T cells. 
Therefore, to maximize the effect of the immune system, it is of a great interest to develop 
a therapy of combined NK and T cell infusion. We hypothesized that chemotherapy 
agents that can sensitize tumors to NK and T cell mediated anti-tumor immune responses 
with combined immunotherapy may result in better clinical responses in patients with 
cancer (Figure 12).  
 
We initially screened several human tumor cell lines following treatment with variety of 
already identified chemotherapy agents and pre-clinical compounds that have potential to 
sensitize tumor cells. The treatments were divided to short-term and long-term exposures 
(3-72 hours) at physiological doses. Following treatments, tumor cells were analyzed for 
expression of diverse membrane-bound recognition proteins including; TRAIL-R1 (DR4), 
TRAIL-R2 (DR5), TRAIL-R3 (DcR1), MICA/B, Nectin-2, PVR, Fas, and MHC class I. 
We found two potential drugs that up-regulate mainly TRAIL-R2 and slightly increased 
TRAIL-R, and some of the stress ligands. I focused on a substance called b-AP15. b-
AP15 is a proteasome inhibitor inhibiting the regulatory subunit of the proteasome 
compared to bortezomib that regulate the core unit 20S (306, 307). Such inhibition of 20S 
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can mediate disturbances in the antigen presenting process which in turn inhibit the 
activation of T cells (308). Cells treated with b-AP15 accumulate polyubiquitinated 
proteins, with similar kinetics to cells treated with bortezomib. b-AP15-induced 
proteasome inhibition was concomitant with the up-regulation of apoptotic markers and 
the accumulation of cell-cycle regulatory proteins, leading to cell cycle arrest and 
apoptosis independent of the tumor suppressor p53 or overexpression of the BCL2 
oncogene, which are implicated in bortezomib resistance (307, 309). Further we 
investigated if tumor cells were more sensitive to killing by NK and T cells following 
treatment with b-AP15 in vitro and in tumor bearing mice. NK cells were isolated and 
expanded from peripheral blood mononuclear cells (PBMC) of healthy donors and 
melanoma patients.  Tumor specific T cells were isolated and expanded from tumor 
biopsies from HLA-A2 positive melanoma patients.  
 
Human tumor cells treated with b-AP15 were significantly more sensitive to killing by 
NK cells and tumor (Mart1) specific T cells. When neutralizing different killing 
pathways, TRAIL-mediated killing was confirmed to be the major mechanism used by 
both NK cells and T cells to target b-AP15 treated tumors. 
 
In vivo, pre-treatment with b-AP15 resulted in augmented T and NK cell of tumors in 
both immune deficient and immune competent tumor-bearing mice. Thus, targeting 
tumors with both the innate and adaptive arm of the immune system might lead to 
beneficial anti-tumor effects in patients with cancer.  
Figure 12: Tumor cells with heterogeneous expression of MHC I are easier to target by combination of 
NK cells and T cells. We show that treatment with b-AP15 increases tumor susceptibility to NK and T cell 
killing by upregulating TRAIL-R2 expression.     
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Paper II: Activated monocytes augment TRAIL-mediated cytotoxicity by human 
NK cells through release of IFN-γ 
Based on the findings of Paper I, where expression of TRAIL on NK cells is an important 
factor for optimal tumor killing, we sought to investigate whether the expression of 
TRAIL could further be increased on NK cells.  
 
In this paper we investigated if exposure to Zoledronic acid (ZA) would increase the 
expression of TRAIL on human NK cells and lead to increased TRAIL-mediated killing 
of tumor cells. Treatment of purified human NK cells with ZA had no effect on the 
TRAIL expression. However, treatment of PBMC with ZA resulted in increased TRAIL 
expression on NK cells. Thus, accessory cells within the PBMC were needed to induce 
TRAIL expression on NK cells when treated with ZA. In a series of experiments we 
concluded that treatment of monocytes with ZA resulted in increased production of IFN-
γ. Upon neutralization of IFN-γ in co-cultures on monocytes and NK cells in presence of 
ZA, the expression of TRAIL was reduced to background levels (Figure 13).  
 
  
 
Figure 13: ZA induce a cascade of signals in monocytes which result in IFN-γ production which in turn 
upregulate TRAIL on NK cells. These NK cells are highly cytotoxic against tumor cells.  
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Next we investigated the anti-tumor activity of ZA-primed NK cells in tumor-bearing 
mice. Human NK cells were cultured with autologous monocytes in presence or in 
absence of ZA prior infusion. Mice treated with ZA-primed NK cells had significant 
slower tumor progression and prolonged survival compared with unprimed NK cells.     
   
In conclusion, we show that ZA and IL-2-treated monocytes augment TRAIL-mediated 
cytotoxicity by human NK cells. We further identify IFN as the main factor responsible 
for the increased TRAIL expression on human NK cells. In a recent randomized phase III 
study, adjuvant therapy with ZA showed no clinical benefit in patients with breast cancer 
(310). On the other hand, another study showed that treatment with ZA in combination 
with IL-2 resulted in sustained serum levels of TRAIL, which correlated with improved 
clinical outcome in patients with hormone-refractory prostate cancer (311). Our findings 
suggest a new strategy to augment NK-cell anti-tumor activity by ex vivo exposure to ZA 
and IL-2, and infusion of such NK cells could potentially result in improved clinical 
outcome in patients with cancer. 
 
 
Paper III: Regulation of natural killer cell responses by dendritic cells via 
lymphotoxin-alpha, interleukin-12, and tumor growth factor-beta 
 
Driven by the findings in Paper II, we decided to investigate whether also monocyte-
derived DC would activate NK cells in the presence of ZA. Intriguingly, we found that 
the NK cell activity was impaired in presence of DC compared with when cultured alone. 
While several studies have shown increased NK cell activity in pre-clinical murine 
models of DC vaccination, much less is known about the role of DC vaccines in shaping 
natural killer (NK) cell responses in patients with cancer. To study NK cell responses 
following interaction with DC in vivo, we collected blood from chronic lymphatic 
leukemia (CLL) and melanoma patients before and after DC-vaccination. Compared to 
pre-vaccination, the expression of the activation receptors NKp30/46 and CD16 was 
significantly reduced on NK cells in post-vaccination samples from patients with CLL. 
We next investigated the mechanisms of DC-mediated suppression of NK cell responses. 
We were able to confirm the previous findings showing that DC enhance proliferation, 
cytotoxicity, and IFN-γ production in resting NK cells. However, in presence of IL-2, DC 
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suppressed these NK cell responses. IL-2 increases phosphorylation of STAT-3 and high 
phosphorylation status has been reported to be associated with negative regulation of DC 
function (312). Therefore, we next inhibited STAT-3 in DC prior to co-culture with NK 
cells. In these conditions, DC did no longer suppress NK cell activity. We further found 
that suppression of NK cell activity by DC was independent on contact. We next analyzed 
production of cytokines by DC and STAT-3 inhibited DC and found a pronounced 
increase of IL-12, lymphotoxin-alpha (LTA), and down-regulation of TGF-β production 
by STAT-3-inhibited DC compared with untreated DC. These three cytokines act in 
concert to influence the activity of NK cells. TGF-β reduced the production of IL-12 and 
LTA in co-cultures of NK cells and DC and IL-12 or LTA was essential for maintained 
NK cell activity. Taken together, we conclude that the cross-talk between DC and NK 
cells is regulated through production of LTA, IL-12, and TGF-β (Figure 14). It might be 
of high importance to manufacture DC with low STAT3 phosphorylation to avoid 
suppression of NK cell responses.   
 
 
Figure 14: NK-DC crosstalk before and after STAT3 inhibition.  
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Paper IV: Myeloid-derived suppressor cells inhibit NK cell activity through 
prostaglandin-E2 regulated TGF-β production 
 
In this study we investigated the role of MDSCs on NK cells. We previously developed a 
co-culture system where COX-2 expression by tumor cells was essential to convert 
monocytes into MDSC-like cells (223). Here we treated monocytes with recombinant 
PGE2 to induce MDSC-like cells. PGE2 bound to the EP2 and EP4 receptors resulting in 
decreased expression of HLA-DR, and increased levels of phosphorylated p38MAPK and 
ERK, and increased production of TGF-β. These cells indeed suppressed the activity of 
NK cells. Similar to patient-derived MDSCs, the PGE2-treated monocytes suppressed NK 
cell responses by production of TGF-β (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Mechanism of MDSC induction and suppression of NK cells. 
 
  
 
To assess the functional consequences of COX-2 expressing tumors in vivo, we used a 
murine model, where control or COX-2-silenced 4T1 mammary carcinoma cells were s.c 
inoculated. Significantly higher percentage of CD11b
+
Gr1
+
 MDSCs and lower 
percentages of NK cell population were observed in mice inoculated with COX-2 silenced 
4T1 cells compared with wt 4T1 cells. Furthermore, mice bearing COX-4 silenced 4T1 
EP
4 
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tumor had better rejected NK cell-sensitive YAC-1 cells compared with mice bearing wt 
4T1 cells. Taken together, our data demonstrated a novel role of PGE2 in inducing 
suppressive functions of MDSCs on NK cells, primarily by activating the production of 
TGF-β in myeloid cells through EP2/4 receptor and p38MAPK/ERK pathway. Given the 
prevalence of COX-2 over-expression and the central immune-regulatory role of TGF-β, 
these mechanisms might be relevant in several types of human cancers. Consequently, 
combining COX-2 inhibitors or EP antagonists with adoptive NK cell therapy may 
consolidate and enhance the clinical benefits for cancer patients. 
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4 OVERALL CONCLUSIONS 
 
Although NK cells are “natural” in their targeting of tumors, by reading this book I hope I 
have convinced you that determining their responses in the tumor microenvironment is no 
bed of roses. As a tumor immunologist I believe in the immune surveillance theory, 
though the failure of the immune system to eliminate tumors may be in part due to 
sustained immunological selection pressure on tumor cells resulting in the development of 
tumor escape variants that are effectively invisible to the immune system. The tumor 
microenvironment is a complex network consisting of many different cells and factors 
that all contribute to diminishing the immune effectors to eliminate cancer. The miserable 
have no other medicine but only hope (William Shakespeare). About immunotherapy we 
have not only hope, we have clinical evidences that claiming our movement towards 
effective immunotherapy in cancer patients. 
 
In this thesis new strategies to efficient NK cell-based therapy have been suggested and 
new findings about understanding the mechanisms of suppressing NK cells in tumors 
have been revealed (Figure 16). To be suppressed or activated?     
 
Figure 16: Overall achievement of the thesis. 
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